Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pancreatic Cancer|Acute Myeloid Leukemia|Prolymphocytic Leukemia|Prostate Cancer|Melanoma|Multiple Myeloma|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Adenocarcinoma|Chronic Lymphoid Leukemia|Esophageal Cancer|Lymphoma, Non-Hodgkin|Acute Erythroblastic Leukemia|Kidney Cancer|Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Renal Cell Carcinoma|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Basophilic Leukemia|Peritoneal Cancer|Acute Megakaryoblastic Leukemia|Ovarian Cancer|Hypereosinophilic Syndrome|Acute Eosinophilic Leukemia|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Adult T-Cell Leukemia-Lymphoma|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Mycosis Fungoides|Liver Cancer|Waldenstrom Macroglobulinemia|Follicular Lymphoma|Preleukemia|Large-Cell Anaplastic Lymphoma|Immunoblastic Lymphadenopathy|Sezary Syndrome|Breast Cancer|Thromboembolism|Multiple Sclerosis|Endometrial Cancer|T-Cell Cutaneous Lymphoma|Lymphomatoid Granulomatosis|Large-Cell Immunoblastic Lymphoma|B-Cell Marginal Zone Lymphoma|Leukemia, Plasma Cell|Seminoma|Squamous Cell Carcinoma|Head and Neck Cancer|Sarcoma|Gastrointestinal Cancer|Germinoma|Testicular Cancer
Phase 1: Skin Cancer|Breast Cancer|Prostate Cancer|Hairy Cell Leukemia|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Lymphocytic Chronic B-Cell Leukemia|Optic Nerve Glioma|Optic Nerve Cancer|Retinoblastoma|Follicular Lymphoma|Lymphoproliferative Disorders|B-Cell Marginal Zone Lymphoma|Oncology Solid Tumor Unspecified|Prolymphocytic Leukemia|Soft Tissue Cancer|Lymphoid Leukemia|Melanoma|Hypothalamic Cancer|Peripheral Neuroectodermal Tumors, Primitive|Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Neuroblastoma|Lymphoma, Non-Hodgkin|Acute Myelomonocytic Leukemia|Astrocytoma|Osteosarcoma|Embryonal Rhabdomyosarcoma|Medulloblastoma|Sarcoma, Ewing|Ependymoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Brain Stem Cancer|Wilms Tumor|Diffuse Large B-Cell Lymphoma|Lymphoma, B-Cell|Cerebellar Cancer|Chronic Myelomonocytic Leukemia|Acute Eosinophilic Leukemia|Acute Myeloid Leukemia|Primitive Neuroectodermal Tumors|Supratentorial Cancer|Acute Monocytic Leukemia|Hypereosinophilic Syndrome|Liver Cancer|Multiple Myeloma|Acute Lymphoid Leukemia|Blast Crisis|Chronic Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts|Male Breast Cancer|Kidney Cancer|Adenocarcinoma|Sarcoma|Acute Erythroblastic Leukemia|Kidney Diseases|Acute Basophilic Leukemia|Acute Megakaryoblastic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Gastrointestinal Stromal Tumors|Lymphoma|Non-Small-Cell Lung Cancer|Leukemia|Intestinal Cancer|Pancreatic Cancer|Mesothelioma|Thrombocytopenia|Anemia, Refractory|Esophageal Cancer|Oncology Hematological Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-001178-41 |
2017-001178-41 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-10-10 |
2022-03-13 |
Treatments |
|
NCT03593915 |
TPI-ALV-102 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2021-08-16 |
13% |
2023-10-18 |
Primary Endpoints |
NCT03969420 |
TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
36% |
2023-10-18 |
|
NCT03441555 |
M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
25% |
2023-10-18 |
Primary Endpoints|Treatments |
NCT04493099 |
NCI-2020-05266 | P2 |
Withdrawn |
Acute Myeloid Leukemia |
2020-10-12 |
2020-11-13 |
||
JapicCTI-183964 |
JapicCTI-183964 | P1 |
Unknown |
Acute Myeloid Leukemia |
2020-03-31 |
|||
NCT03563560 |
AML | P1 |
Completed |
Acute Myeloid Leukemia |
2020-03-31 |
32% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT03298984 |
TPI-ALV-101 | P1 |
Completed |
Acute Myeloid Leukemia |
2020-03-20 |
16% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT02520011 |
TPI-ALV-201 | P2 |
Terminated |
Acute Myeloid Leukemia |
2020-02-12 |
70% |
2024-11-27 |
Primary Endpoints |
NCT00634244 |
NCI-2009-00520 | P2 |
Completed |
Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia |
2014-09-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00957905 |
NCI-2011-01405 | P2 |
Completed |
Ovarian Cancer|Seminoma|Testicular Cancer|Germinoma |
2014-08-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT01349972 |
NCI-2011-02587 | P2 |
Completed |
Acute Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Myelodysplastic Syndrome |
2014-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00094978 |
05-C-0010 | P1 |
Terminated |
Esophageal Cancer|Mesothelioma|Non-Small-Cell Lung Cancer |
2013-05-20 |
2019-03-21 |
Treatments |
|
NCT00735930 |
NCI-2009-00269 | P1 |
Completed |
Lymphoma, B-Cell|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Anemia, Refractory|Chronic Lymphoid Leukemia|Thrombocytopenia|Prolymphocytic Leukemia |
2013-03-01 |
2019-03-18 |
Treatments |
|
NCT00101231 |
NCI-2012-01461 | P1 |
Terminated |
Hypereosinophilic Syndrome|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Acute Eosinophilic Leukemia|Chronic Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Blast Crisis|Acute Basophilic Leukemia|Acute Megakaryoblastic Leukemia|Chronic Myeloid Leukemia|Acute Erythroblastic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia |
2012-11-01 |
2019-03-21 |
Treatments |
|
NCT00377104 |
NCI-2009-00161 | P1 |
Terminated |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2012-11-01 |
2019-03-21 |
Treatments |
|
NCT00082784 |
NCI-2009-00058 | P1 |
Completed |
B-Cell Marginal Zone Lymphoma|Multiple Myeloma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Diffuse Large B-Cell Lymphoma |
2012-10-01 |
2019-03-21 |
Treatments |
|
NCT00112684 |
NCI-2009-00135 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2012-07-01 |
2019-03-21 |
Treatments |
|
NCT00445341 |
07-C-0081 | P2 |
Completed |
Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma |
2012-04-30 |
2019-03-21 |
||
NCT00991952 |
NCI-2011-03825 | P2 |
Completed |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2012-02-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2006-006152-34 |
2006-006152-34 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia |
2012-01-16 |
2022-03-12 |
Treatments |
|
NCT00464633 |
EFC6663 | P2 |
Completed |
Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2011-12-01 |
2019-03-21 |
Treatments |
|
NCT00098579 |
NCI-2009-00048 | P1 |
Completed |
Gastrointestinal Stromal Tumors|Sarcoma |
2011-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00112723 |
NCI-2011-01346 | P2 |
Terminated |
Large-Cell Anaplastic Lymphoma|Immunoblastic Lymphadenopathy|Sezary Syndrome|Follicular Lymphoma|Leukemia, Plasma Cell|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|Multiple Myeloma|Multiple Sclerosis|Lymphocytic Chronic B-Cell Leukemia|Large-Cell Immunoblastic Lymphoma|Lymphomatoid Granulomatosis|B-Cell Marginal Zone Lymphoma |
2011-02-01 |
2020-10-26 |
Primary Endpoints |
|
NCT00470197 |
NCI-2009-00243 | P1 |
Completed |
Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Acute Lymphoid Leukemia|Acute Monocytic Leukemia|Acute Erythroblastic Leukemia|Acute Myeloid Leukemia |
2011-01-01 |
2024-11-27 |